Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Meropenem × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Febrile Neutropenia 5 Neoplasms 3 Urinary Bladder Neoplasms 1 Sepsis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Other Infectious Diseases 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Fever 1 Emergencies 1

Interventions

Gemcitabine 132 Cisplatin 97 pembrolizumab 68 Cystectomy 41 Paclitaxel 37 Carboplatin 36 Nivolumab 35 Docetaxel 35 Mitomycin 32 atezolizumab 29 durvalumab 28 Radiotherapy 27 Magnetic Resonance Spectroscopy 27 avelumab 23 Specimen Handling 22 Cystoscopy 22 Doxorubicin 20 BCG Vaccine 20 Fluorouracil 18 enfortumab vedotin 16 Methotrexate 15 Vinblastine 14 Standard of Care 14 Ipilimumab 13 Filgrastim 13 5-aminolevulinic acid hexyl ester 13 vinflunine 12 Biopsy 12 Transurethral Resection of Bladder 11 Surgical Procedures, Operative 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡